Clinical Trial Update: Safety and Efficacy of Resticutis Compared to Platelet-Poor Plasma for Treating Diabetic Foot Ulcers [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial comparing Resticutis to platelet-poor plasma for diabetic foot ulcers, with phase 1 and phase 2 stages; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer

Drugs mentioned

• Platelet-Poor Plasma (Platelet-Poor Plasma)
• Resticutis

Snippet

Sponsor: Hanan Jafar | Conditions: Diabetic Foot Ulcer | Phase 1, Phase 2 | Status: UNKNOWN